Get the Stockscreener App
6.035
0.25%
0.015
After Hours:
6.04
0.005
+0.08%
Nyxoah Sa stock is traded at $6.035, with a volume of 76,631.
It is up +0.25% in the last 24 hours and down -42.03% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$6.02
Open:
$5.98
24h Volume:
76,631
Relative Volume:
0.67
Market Cap:
$223.82M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-3.594
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
+0.42%
1M Performance:
-42.03%
6M Performance:
-36.81%
1Y Performance:
-36.81%
1-Day Range:
$5.9005
$6.09
1-Week Range:
$5.62
$6.3677
52-Week Range:
$5.55
$12.21
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
6.035 | 223.82M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to Connect - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A.NYXH - Bluefield Daily Telegraph
Nyxoah Announces Conditional Issuance of 5 Million Shares - TipRanks
Conditional Issuance of Shares - The Manila Times
Nyxoah Expands ATM Program: 5.66M Total Shares Now Available for Market Sale - Stock Titan
Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Stockholders to Connect - markets.businessinsider.com
Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Nyxoah’s Final Hurdle for FDA Approval of Genio Neurostimulator for Sleep Apnea - Sleep Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Investors to Inquire about Securities Investigation - ACCESS Newswire
Nyxoah Expects to Meet Final FDA Requirements for Sleep Apnea Treatment Device Approval in Q2 - MarketScreener
Nyxoah Expects Q2 Approval of Genio System from US FDA - MarketScreener
Nyxoah Provides Update on FDA Approvable Letter for Genio System - The Manila Times
Nyxoah Provides Update On FDA Approvable Letter For Genio System - MarketScreener
FDA Signals Green Light for Revolutionary Sleep Apnea TreatmentJust One Step Away - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Investors to Reach Out - markets.businessinsider.com
NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Invest - GuruFocus
NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - GlobeNewswire Inc.
Nyxoah S.A. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Oppenheimer maintains $13 target on Nyxoah shares post-FDA talks By Investing.com - Investing.com South Africa
Oppenheimer maintains $13 target on Nyxoah shares post-FDA talks - Investing.com
Nyxoah S.A. Investors: Company Investigated By The Portnoy Law Firm - menafn
HC Wainwright Comments on Nyxoah’s Q1 Earnings (NASDAQ:NYXH) - Defense World
Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
HC Wainwright Lowers Nyxoah (NASDAQ:NYXH) Price Target to $15.00 - Defense World
Nyxoah SA: A Medical Technology Company with a Big Loss - RagingBull
Nyxoah announces FDA approvable letter for Genio pre-market approval application - TipRanks
Nyxoah Says FDA Issues Approvable Letter for Genio System - MarketScreener
FDA Issues Approvable Letter For Nyxoah's Genio® System - TradingView
FDA Clears Path Forward for Nyxoah's Revolutionary Sleep Apnea Treatment - Stock Titan
Stifel Nicolaus Has Lowered Expectations for Nyxoah (NASDAQ:NYXH) Stock Price - Defense World
Stifel cuts Nyxoah stock price target to $15, maintains Buy By Investing.com - Investing.com Canada
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates - MSN
(NYXH) Investment Analysis - Stock Traders Daily
Stifel cuts Nyxoah stock price target to $15, maintains Buy - Investing.com
Nyxoah S.A. (NASDAQ:NYXH) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on Nyxoah shares, $17 target - Investing.com
Nyxoah SA (NYXH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic US ... By GuruFocus - Investing.com Canada
Nyxoah Reports 2024 Financial Results and U.S. Launch Plans - TipRanks
Nyxoah Sa’s Earnings Call: Efficacy and Expansion - TipRanks
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results - The Manila Times
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 - The Manila Times
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):